Document Detail


Second malignancies after treatment for Hodgkin's disease.
MedLine Citation:
PMID:  11911408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem. The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data. Six hundred and sixty five patients with HD were treated in our department, between 1978 and 1996. Second neoplasm developed in 32 cases (4.8%). Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia. Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years. Five patients received chemo- and radiotherapy and in two cases chemotherapy was used. Three of the seven patients are alive. Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed. Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years. Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy. Eleven patients had solid tumors in the region irradiated earlier. Ten out of the 25 patients are alive, three patients' present state is unknown. Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival. It is necessary to investigate the impact of additional risk factors. Careful, lifelong observation is indicated for patients with HD, with special attention given to new clinical signs and symptoms.
Authors:
E Várady; B Deák; Z S Molnár; A Rosta; T Schneider; O Esik; S Eckhardt
Related Documents :
7694148 - Escalated as compared with standard doses of doxorubicin in bacop therapy for patients ...
18284718 - Prophylactic use of filgrastim with abvd and beacopp chemotherapy regimens for hodgkin ...
24734198 - Outcomes and control rates for i-125 plaque brachytherapy for uveal melanoma: a communi...
10400368 - Hodgkin's disease and non-hodgkin's lymphoma.
8281458 - Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (dicep) ...
4080638 - Biology of metastasizing ameloblastoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  42     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:    2001 Nov-Dec
Date Detail:
Created Date:  2002-03-25     Completed Date:  2002-08-13     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  1275-81     Citation Subset:  IM    
Affiliation:
Department of Chemotherapy A, National Institute of Oncology, Budapest, Hungary. varadi@oncol.hu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / adverse effects
Female
Hodgkin Disease / therapy*
Humans
Male
Middle Aged
Neoplasms, Second Primary / epidemiology*,  etiology
Radiotherapy / adverse effects
Time Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
Next Document:  Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patien...